BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1004 related articles for article (PubMed ID: 35299965)

  • 1. The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study.
    Farhadi-Azar M; Behboudi-Gandevani S; Rahmati M; Mahboobifard F; Khalili Pouya E; Ramezani Tehrani F; Azizi F
    Front Endocrinol (Lausanne); 2022; 13():825528. PubMed ID: 35299965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Hidden Link between Polycystic Ovary Syndrome and Kidney Stones: Finding from the Tehran Lipid and Glucose Study (TLGS).
    Rostami Dovom M; Rahmati M; Amanollahi Soudmand S; Ziaeefar P; Azizi F; Ramezani Tehrani F
    Diagnostics (Basel); 2023 Aug; 13(17):. PubMed ID: 37685351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H; Tanir HM; Yildiz Z
    Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran.
    Tehrani FR; Rashidi H; Khomami MB; Tohidi M; Azizi F
    Reprod Biol Endocrinol; 2014 Sep; 12():89. PubMed ID: 25224635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of community-based reference ranges to estimate the prevalence of polycystic ovary syndrome by the recognised diagnostic criteria, a cross-sectional study.
    Skiba MA; Bell RJ; Herbert D; Garcia AM; Islam RM; Davis SR
    Hum Reprod; 2021 May; 36(6):1611-1620. PubMed ID: 33846715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-polycystic ovary syndrome and polymenorrhoea as new facets of polycystic ovary syndrome (PCOS): Evidences from a single centre data set.
    Ganie MA; Rashid A; Baba MS; Zargar MA; Wani IA; Nisar S; Wani IA; Douhath S; Sriwastawa M; Geer MI; Asrar MM; Kutum R; Hassan S; Khan S; Rafi W; Bhat DA; Showkat W; Sahar T; Choh NA; Khurshid R; Mudassar S; Shah ZA; Shabir I; Sofi SA; Gupta N; Hafeez I; Sreenivas V
    Clin Endocrinol (Oxf); 2023 Dec; 99(6):566-578. PubMed ID: 37656656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype.
    Legro RS; Chiu P; Kunselman AR; Bentley CM; Dodson WC; Dunaif A
    J Clin Endocrinol Metab; 2005 May; 90(5):2571-9. PubMed ID: 15713728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic syndrome and metabolic risk profile according to polycystic ovary syndrome phenotype.
    Bil E; Dilbaz B; Cirik DA; Ozelci R; Ozkaya E; Dilbaz S
    J Obstet Gynaecol Res; 2016 Jul; 42(7):837-43. PubMed ID: 27071345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis.
    Bozdag G; Mumusoglu S; Zengin D; Karabulut E; Yildiz BO
    Hum Reprod; 2016 Dec; 31(12):2841-2855. PubMed ID: 27664216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of metabolic syndrome in adolescents with different phenotypes of PCOS.
    Altintas KZ; Dilbaz B; Cirik DA; Ozelci R; Zengin T; Erginay ON; Dilbaz S
    Ginekol Pol; 2017; 88(6):289-295. PubMed ID: 28727126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria.
    Yildiz BO; Bozdag G; Yapici Z; Esinler I; Yarali H
    Hum Reprod; 2012 Oct; 27(10):3067-73. PubMed ID: 22777527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria.
    Jamil AS; Alalaf SK; Al-Tawil NG; Al-Shawaf T
    Arch Gynecol Obstet; 2016 Feb; 293(2):447-56. PubMed ID: 26408006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome.
    Fraissinet A; Robin G; Pigny P; Lefebvre T; Catteau-Jonard S; Dewailly D
    Hum Reprod; 2017 Aug; 32(8):1716-1722. PubMed ID: 28854589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of 2-Arachidonoylglycerol Levels in Polycystic Ovary Syndrome in the Context of Hormonal and Metabolic Alterations and Across the Classical Phenotypes.
    Kabakchieva P; Gateva A; Hristova J; Georgiev T; Kamenov Z
    Cannabis Cannabinoid Res; 2023 Aug; 8(4):634-641. PubMed ID: 35235418
    [No Abstract]   [Full Text] [Related]  

  • 16. [Polycystic ovary syndrome: is there a rise in the prevalence?].
    Carmona-Ruiz IO; Saucedo-de la Llata E; Moraga-Sánchez MR; Romeu-Sarró A
    Ginecol Obstet Mex; 2015 Dec; 83(12):750-9. PubMed ID: 27290799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors.
    Broekmans FJ; Knauff EA; Valkenburg O; Laven JS; Eijkemans MJ; Fauser BC
    BJOG; 2006 Oct; 113(10):1210-7. PubMed ID: 16972863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The phenotypic diversity in per-follicle anti-Müllerian hormone production in polycystic ovary syndrome.
    Alebić MŠ; Stojanović N; Duhamel A; Dewailly D
    Hum Reprod; 2015 Aug; 30(8):1927-33. PubMed ID: 26048913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature.
    Azziz R
    J Clin Endocrinol Metab; 2006 Mar; 91(3):781-5. PubMed ID: 16418211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria.
    Jamil AS; Alalaf SK; Al-Tawil NG; Al-Shawaf T
    Reprod Health; 2015 Jan; 12():7. PubMed ID: 25595199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.